Grants and Contracts per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Master of Business Administration, Univ Of Kentucky
1999
Post Doctoral Fellow, Johns Hopkins University, The
1981
Residency, Univ Of Virginia
1979
Internship, West Virginia University
1976
Doctor of Medicine, West Virginia University
1975
Bachelor of Arts, Johns Hopkins University, The
1970
Fingerprint
Dive into the research topics where John Slevin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration from the last 5 years on country level. Dive into details by clicking on the dots.
-
Direct delivery of an investigational cell therapy in patients with Parkinson's disease: An interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design
Quintero, J. E., Slevin, J. T., Gurwell, J. A., McLouth, C. J., El Khouli, R., Chau, M. J., Guduru, Z., Gerhardt, G. A. & Van Horne, C. G., Jul 1 2022, In: BMJ Neurology Open. 4, 2, e000301.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Encephalopathy and complex hyperkinesia in a patient with severe acute respiratory syndrome coronavirus-2 infection
Li, W., Coskun, E. P., Berger, R., Slevin, J. T. & Pettigrew, L. C., 2021, In: Journal of Movement Disorders. 14, 2, p. 173-175 3 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
Gait and balance changes with investigational peripheral nerve cell therapy during deep brain stimulation in people with parkinson’s disease
Gera, G., Guduru, Z., Yamasaki, T., Gurwell, J. A., Chau, M. J., Krotinger, A., Schmitt, F. A., Slevin, J. T., Gerhardt, G. A., van Horne, C. & Quintero, J. E., 2021, In: Brain Sciences. 11, 4, 500.Research output: Contribution to journal › Article › peer-review
Open Access -
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Mar 2021, In: The Lancet Neurology. 20, 3, p. 182-192 11 p.Research output: Contribution to journal › Article › peer-review
Open Access48 Scopus citations -
GDNF clinical trials for Parkinson’s disease: a critical human dimension
Gash, D. M., Gerhardt, G. A., Bradley, L. H., Wagner, R. & Slevin, J. T., Oct 1 2020, In: Cell and Tissue Research. 382, 1, p. 65-70 6 p.Research output: Contribution to journal › Article › peer-review
10 Scopus citations